Too early to say if cloud over pharma stocks has fully lifted, says BMO's Seigerman

Core Viewpoint - The healthcare sector, particularly pharmaceuticals, is under pressure with valuations nearing 15-year lows, raising questions about whether it presents a genuine investment opportunity or remains a value trap [1] Group 1: Market Sentiment and Drug Pricing - The recent announcement from Pfizer indicates that drug companies can comply with the Trump administration's demands without significant concessions, which is viewed positively for the stock and the sector [2] - The "most favored nations" pricing has been a significant concern for the sector, deterring generalist investors throughout the year [2][3] Group 2: Company-Specific Insights - Pfizer's recent developments, including the Metsa acquisition and positive mid-stage results for Metsa's GLP-1 candidate, have shifted sentiment positively towards the company [5][7] - Pfizer's stock has increased by 7% recently, and it is considered a value play with a mid-single-digit valuation and a 7% yield [6] - Despite challenges with loss of exclusivity for some products, Pfizer is expected to maintain a strong position as long as it focuses on margin expansion and pipeline development [8]